US drug maker Medivation (Nasdaq: MDVN) and Japanese drug major Astellas Pharma (TYO: 4503) have announced final results on the primary and secondary efficacy endpoints from the Phase III PREVAIL trial of Xtandi (enzalutamide) in patients with chemotherapy-naïve metastatic prostate cancer who have failed androgen deprivation therapy and have few or no symptoms.
Study results
The PREVAIL study results in men with metastatic prostate cancer who have progressed on androgen deprivation therapy show that treatment with enzalutamide demonstrated a statistically significant overall survival benefit compared with placebo treatment. Enzalutamide reduced the risk of death by 29% compared with placebo. This benefit was observed despite substantial use of subsequent therapies (40% in the enzalutamide and 70% in the placebo groups).It was announced in October that the Independent Data Monitoring Committee (IDMC) recommended the study be stopped and patients treated with placebo be offered enzalutamide (The Pharma Letter October 23, 2013).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze